Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 114Neoplasms 28Lung Neoplasms 24Non-Squamous Non-Small Cell Lung Cancer 21Pancreatic Neoplasms 13Colorectal Neoplasms 6Neoplasm Metastasis 5Breast Neoplasms 4Respiratory Tract Neoplasms 3Respiratory Tract Diseases 3Lymphoma 3Thoracic Neoplasms 2Solid Tumors 2Recurrence 2Neoplasms by Site 2Lung Diseases 2Familial ependymoma 2Ependymoma 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Carcinoma 2Bronchial Neoplasms 2Advanced Solid Tumors 2Vascular Diseases 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Smoking 1Small Cell Lung Carcinoma 1

Interventions

zenocutuzumab 2seribantumab 2pembrolizumab 1patritumab 1osimertinib 1exemestane 1cemiplimab 1Vinorelbine 1Vascular Endothelial Growth Factor A 1Trastuzumab 1Paroxetine 1Paclitaxel 1Letrozole 1Itraconazole 1Fulvestrant 1Erlotinib Hydrochloride 1Docetaxel 1Carboplatin 1Antibodies, Bispecific 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lethal Congenital Contracture Syndrome 2 × Erlotinib Hydrochloride × Clear all
NCT00994123 2016-08-22

A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Merrimack Pharmaceuticals

Phase 1/2 Completed
162 enrolled 11 charts
Thoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡